This study assessed the radioactivity level of Iju River sediments and its associated radiological risks exposure to human. Gamma absorbed dose rates were measured using a portable gamma spectrometer at an interval of 50 m between each point (Model No:RS-125 manufactured by Canadian Geophysical Institute). The measured absorbed gamma dose rates range from 22 to 59 nGy/h with the highest value noted in site 13. The mean activity concentrations of U-238, Th-232 and K-40 from Iju river sediments were 24.1 ± 0.4 Bq/kg, 35.2 ± 1.1 Bq/kg and 501.0 ± 11.1 Bq/kg, which were lower than the world average values of 32 and 45 for U-238 and Th-232 by 25% and 21% and higher than 412 Bq/kg for K-40 by a factor of 0.22 (22%).•This highest value of K-40 found in site 6 may be due to the presence of feldspartic minerals buried in the sediments.•Consequently, the radiological hazard indices were below the permissible limits except the mean value of 28 × 10 for excess lifetime cancer risk (ELCR) for the samples collected in site 6, which is higher than the average world value of 0.29 × 10 by a factor of 0.03.•The regression model indicates that Th-232 attributes more radioactivity impacts on the soil sediments than the contributions of U-232 and K-40, as such, presumed to be the radionuclide parameter controlling the depositional process in the region.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581974 | PMC |
http://dx.doi.org/10.1016/j.mex.2020.101086 | DOI Listing |
Vet Parasitol
January 2025
Laboratório de Quimioterapia Experimental em Parasitologia Veterinária (LQEPV), Universidade Federal Rural do Rio de Janeiro, Seropédica, Brazil; Departamento de Parasitologia Animal, Instituto de Medicina Veterinária, Universidade Federal Rural do Rio de Janeiro, Seropédica, Rio de Janeiro, Brazil.
This study investigated the combined effect of trans-anethole, carvacrol and thymol on third-instar larvae of C. hominivorax. For this experiment, third-stage larvae of C.
View Article and Find Full Text PDFOncologist
January 2025
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Thoracic Oncology, 1066 CX Amsterdam, The Netherlands.
Introduction: We describe the safety of sotorasib monotherapy in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) and discuss practical recommendations for managing key risks.
Methods: Incidence rates of treatment-related adverse events (TRAEs) were pooled from 4 clinical trials: CodeBreaK 100 (NCT03600883), CodeBreaK 101 (NCT04185883), CodeBreaK 105 (NCT04380753), and CodeBreaK 200 (NCT04303780) and graded according to CTCAE v5.0.
J Funct Morphol Kinesiol
January 2025
Department of Neurosciences, Faculty of Medicine, Laval University, Québec, QC G1V 0A6, Canada.
Cardiotoxicity, cardiovascular diseases (CVDs), hypertension, hepatotoxicity, and respiratory problems occurring several months to several years post-chemotherapy and/or radiotherapy are increasingly documented by scientists and clinicians. Anthracyclines, for example, were discovered in the late 1960s to be dose-dependently linked to induced cardiotoxicity, which frequently resulted in cardiomyopathy and heart failure. Most of those changes have also been associated with aging.
View Article and Find Full Text PDFPediatr Rep
January 2025
Emergency Medical Services Department, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia.
Background/objectives: This study aimed to assess and compare the rates of medication error (ME) using the PediSTAT application compared to the conventional method of calculating the correct dose and determining the appropriate route of medication administration for common pediatric emergencies.
Methods: A prospective cross-sectional study design was used for the study. Data were collected using a questionnaire that was distributed to certified paramedics holding a bachelor's degrees or higher and working in Riyadh City, Saudi Arabia.
J Eur Acad Dermatol Venereol
January 2025
Pfizer Inc, Paris, France.
Background: ALLEGRO-LT is an ongoing, long-term, open-label, multicentre, phase 3 study of ritlecitinib in adults and adolescents with alopecia areata (AA).
Objectives: To evaluate ritlecitinib safety and efficacy through Month 24 in patients with AA and ≥25% scalp hair loss.
Methods: ALLEGRO-LT enrolled rollover patients who previously received study intervention in either ALLEGRO phase 2a or 2b/3 studies and de novo patients who had not received treatment in either study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!